UA79610C2 - Solid dispersion composition - Google Patents
Solid dispersion composition Download PDFInfo
- Publication number
- UA79610C2 UA79610C2 UA20041109330A UA20041109330A UA79610C2 UA 79610 C2 UA79610 C2 UA 79610C2 UA 20041109330 A UA20041109330 A UA 20041109330A UA 20041109330 A UA20041109330 A UA 20041109330A UA 79610 C2 UA79610 C2 UA 79610C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- solid dispersion
- glycol
- polyoxyethylene
- dispersion composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 54
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000012876 topography Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 5
- HEUAVAATAFEENP-UHFFFAOYSA-N 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CC=C1 HEUAVAATAFEENP-UHFFFAOYSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 description 30
- -1 hydroxypropoxy groups Chemical group 0.000 description 25
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 229920001451 polypropylene glycol Polymers 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000000790 scattering method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010016818 Fluorosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000004042 dental fluorosis Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37241602P | 2002-04-16 | 2002-04-16 | |
| PCT/JP2003/004762 WO2003086405A1 (fr) | 2002-04-16 | 2003-04-15 | Composition de dispersion solide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79610C2 true UA79610C2 (en) | 2007-07-10 |
Family
ID=29250849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041109330A UA79610C2 (en) | 2002-04-16 | 2003-04-15 | Solid dispersion composition |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6753330B2 (es) |
| EP (1) | EP1495759A4 (es) |
| JP (1) | JP4295629B2 (es) |
| KR (1) | KR20040101437A (es) |
| CN (1) | CN1291719C (es) |
| AU (1) | AU2003235156B2 (es) |
| BR (1) | BR0309212A (es) |
| CA (1) | CA2481595A1 (es) |
| EA (1) | EA007153B1 (es) |
| HK (1) | HK1082669A1 (es) |
| HR (1) | HRP20040959A2 (es) |
| IL (2) | IL164206A0 (es) |
| IS (1) | IS7488A (es) |
| MX (1) | MXPA04010174A (es) |
| MY (1) | MY128945A (es) |
| NO (1) | NO20044337L (es) |
| NZ (1) | NZ535541A (es) |
| PL (1) | PL372980A1 (es) |
| TW (1) | TWI319772B (es) |
| UA (1) | UA79610C2 (es) |
| WO (1) | WO2003086405A1 (es) |
| ZA (1) | ZA200407657B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8105630B2 (en) * | 2003-04-29 | 2012-01-31 | Kowa Co., Ltd. | Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof |
| WO2005012259A1 (ja) * | 2003-07-30 | 2005-02-10 | Kowa Co., Ltd. | オステオポンチン産生抑制方法 |
| US20050220881A1 (en) * | 2003-10-10 | 2005-10-06 | Bvm Holding Co. | Pharmaceutical composition |
| JP2006001859A (ja) * | 2004-06-16 | 2006-01-05 | Shiseido Co Ltd | 絆創膏組成物 |
| WO2006080312A1 (ja) * | 2005-01-25 | 2006-08-03 | Kowa Co., Ltd. | 吸着多孔体の製造法 |
| EP1920772A4 (en) * | 2005-08-31 | 2010-11-17 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR COMBATING RHEUMATOID ARTHRITIS |
| US20080132560A1 (en) * | 2006-11-21 | 2008-06-05 | San-Laung Chow | Solid dispersion composition |
| JP2009155282A (ja) * | 2007-12-27 | 2009-07-16 | Kowa Co | 固体分散体含有医薬組成物 |
| DE102008047910A1 (de) * | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| US11413271B2 (en) * | 2018-06-11 | 2022-08-16 | Abon Pharmaceuticals Llc | Oral eliglustat transmucosal delivery system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4314196A (en) * | 1994-12-21 | 1996-07-10 | Yamanouchi Pharmaceutical Co., Ltd. | Solid composition with improved solubility and absorbability |
| TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| JP3335132B2 (ja) * | 1997-11-19 | 2002-10-15 | 興和株式会社 | 新規ピリダジン誘導体及びこれを有効成分とする医薬 |
| CA2307111C (en) * | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| AU7447900A (en) * | 1999-10-04 | 2001-05-10 | Asahi Kasei Kabushiki Kaisha | Method for improving the solubility of tricyclic amino alcohol derivatives |
| JP2004131393A (ja) * | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
-
2003
- 2003-04-09 MY MYPI20031301A patent/MY128945A/en unknown
- 2003-04-15 KR KR10-2004-7016203A patent/KR20040101437A/ko active IP Right Grant
- 2003-04-15 WO PCT/JP2003/004762 patent/WO2003086405A1/ja active IP Right Grant
- 2003-04-15 UA UA20041109330A patent/UA79610C2/uk unknown
- 2003-04-15 JP JP2003583424A patent/JP4295629B2/ja not_active Expired - Fee Related
- 2003-04-15 IL IL16420603A patent/IL164206A0/xx active IP Right Grant
- 2003-04-15 BR BR0309212-7A patent/BR0309212A/pt not_active IP Right Cessation
- 2003-04-15 CN CNB038083795A patent/CN1291719C/zh not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010174A patent/MXPA04010174A/es active IP Right Grant
- 2003-04-15 AU AU2003235156A patent/AU2003235156B2/en not_active Ceased
- 2003-04-15 PL PL03372980A patent/PL372980A1/xx not_active Application Discontinuation
- 2003-04-15 CA CA002481595A patent/CA2481595A1/en not_active Abandoned
- 2003-04-15 EA EA200401377A patent/EA007153B1/ru not_active IP Right Cessation
- 2003-04-15 EP EP03746488A patent/EP1495759A4/en not_active Withdrawn
- 2003-04-15 NZ NZ535541A patent/NZ535541A/en unknown
- 2003-04-16 TW TW092108801A patent/TWI319772B/zh not_active IP Right Cessation
- 2003-04-16 US US10/414,008 patent/US6753330B2/en not_active Expired - Fee Related
-
2004
- 2004-09-21 IL IL164206A patent/IL164206A/en not_active IP Right Cessation
- 2004-09-22 ZA ZA200407657A patent/ZA200407657B/en unknown
- 2004-10-04 IS IS7488A patent/IS7488A/is unknown
- 2004-10-12 NO NO20044337A patent/NO20044337L/no not_active Application Discontinuation
- 2004-10-13 HR HRP20040959 patent/HRP20040959A2/hr not_active Application Discontinuation
-
2006
- 2006-01-27 HK HK06101306A patent/HK1082669A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040959A2 (en) | 2004-12-31 |
| JPWO2003086405A1 (ja) | 2005-08-18 |
| BR0309212A (pt) | 2005-02-09 |
| JP4295629B2 (ja) | 2009-07-15 |
| KR20040101437A (ko) | 2004-12-02 |
| HK1082669A1 (en) | 2006-06-16 |
| NZ535541A (en) | 2006-09-29 |
| WO2003086405A1 (fr) | 2003-10-23 |
| ZA200407657B (en) | 2006-07-26 |
| AU2003235156A1 (en) | 2003-10-27 |
| US20040019122A1 (en) | 2004-01-29 |
| MY128945A (en) | 2007-03-30 |
| PL372980A1 (en) | 2005-08-08 |
| EA007153B1 (ru) | 2006-08-25 |
| TW200408671A (en) | 2004-06-01 |
| US6753330B2 (en) | 2004-06-22 |
| EP1495759A1 (en) | 2005-01-12 |
| TWI319772B (en) | 2010-01-21 |
| IS7488A (is) | 2004-10-04 |
| AU2003235156B2 (en) | 2007-07-05 |
| MXPA04010174A (es) | 2005-02-03 |
| EP1495759A4 (en) | 2010-12-29 |
| IL164206A (en) | 2008-04-13 |
| CN1291719C (zh) | 2006-12-27 |
| IL164206A0 (en) | 2005-12-18 |
| CN1646128A (zh) | 2005-07-27 |
| NO20044337L (no) | 2004-10-12 |
| CA2481595A1 (en) | 2003-10-23 |
| AU2003235156B9 (en) | 2003-10-27 |
| EA200401377A1 (ru) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2855426T3 (es) | Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen | |
| KR102265644B1 (ko) | 글루코키나아제 활성화제의 경구제제 및 이의 제조방법 | |
| TWI673051B (zh) | 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物 | |
| JP4955685B2 (ja) | ピリミジン−スルファミドを含む安定な医薬組成物 | |
| KR100348842B1 (ko) | 염기성물질로안정화된약제학적조성물 | |
| JP4572300B2 (ja) | ピモベンダン経口投与製剤 | |
| WO2001095912A1 (en) | COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED | |
| JP2010047612A (ja) | ナテグリニド含有製剤 | |
| JP5103173B2 (ja) | ジヒドロピリジン系化合物の分解を防止する方法 | |
| UA79610C2 (en) | Solid dispersion composition | |
| JPWO2007097325A1 (ja) | リン酸オセルタミビル含有医薬組成物 | |
| BG63528B1 (bg) | Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик | |
| JP2004131393A (ja) | 易溶出性製剤 | |
| WO2013114389A1 (en) | Process for preparing solid oral formulations comprising low dose of entecavir | |
| JPH0383922A (ja) | イブプロフェン含有経口投与用組成物 | |
| JP2006056880A (ja) | ピモベンダン経口投与製剤 | |
| WO2019221215A1 (ja) | ルビプロストン含有粒子状医薬組成物 | |
| JP2005060310A (ja) | 不快な味をマスキングする経口投与用製剤 | |
| JP2019073488A (ja) | アプレピタントを有効成分とする医薬錠剤 | |
| CN104640571A (zh) | 包含低熔点丙酸衍生物颗粒的缓释口服剂型 | |
| JP2004067533A (ja) | 易溶出性製剤 | |
| JP2003321397A (ja) | 易溶出性製剤 | |
| JPH04230626A (ja) | 改良されたゲムフィブロジル組成物 | |
| WO2018079734A1 (ja) | メマンチンまたはその薬学上許容される塩を含有する医薬組成物 | |
| WO2013137441A1 (ja) | 経口医薬組成物 |